BioLineRx (BLRX) Gross Profit (2024 - 2026)
BioLineRx (BLRX) posted quarterly Gross Profit of $154000.0 for Q4 2025, down 97.28% year-over-year from $5.7 million in Q4 2024, and down 55.1% quarter-over-quarter from $343000.0 in Q3 2025.
Powered by 
Analysis
BioLineRx (BLRX) Gross Profit (2024 - 2026) Analysis & Trends
BioLineRx's Gross Profit history runs 2 years deep, the most recent figure standing at $154000.0 for Q4 2025.
- In Q4 2025, Gross Profit fell 97.28% year-over-year to $154000.0; the TTM figure through Dec 2025 stood at $950000.0 (down 95.17% YoY), while the FY2025 annual figure was $950000.0, down 95.17% from the prior year.
- Gross Profit for Q4 2025 stood at $154000.0, down from $343000.0 in the prior quarter.
- The five-year high for Gross Profit was $5.7 million in Q4 2024, with the low at $154000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 10 | BioLineRx | 6.46 Bn | 6.46 Bn | 235,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 235,000.00 |
| Mar 31, 2026 | 382,000.00 |
| Dec 31, 2025 | 154,000.00 |
| Sep 30, 2025 | 343,000.00 |
| Jun 30, 2025 | 232,000.00 |
| Mar 31, 2025 | 221,000.00 |
| Dec 31, 2024 | 5.66 Mn |
| Sep 30, 2024 | 4.12 Mn |
| Jun 30, 2024 | 4.50 Mn |
| Mar 31, 2024 | 5.40 Mn |